Fierce Biotech June 6, 2024
Biopharma investment trends continue to shift, with venture funding jumping to $7.4 billion across 188 deals for the first quarter of the year. This compares to $6.3 billion across 248 deals the previous quarter and demonstrates an increase in deal value despite declining deal count, according to PitchBook.
Despite investment trends changing, funding levels quarter over quarter have stayed relatively stable over the past two years, defining a new normal for the sector until federal interest rates change, according to PitchBook’s quarterly biopharma report. The cautiously optimistic climate remains focused on advanced clinical assets, with platform bets mostly out of the picture.
Sector exits, including IPOs and M&A, totaled $6.9 billion across 23 deals in the first quarter, compared with...
Today's Sponsors
Today's Sponsor